Preferential expression of cyclooxygenase-2 in colonic-phenotype of gastric intestinal metaplasia: Association with Helicobacter pylori and gastric carcinoma

Journal of Clinical Gastroenterology

Volumn 40, Issue 2, 2006, Pages 122-128

  Sun, John H ^a   Das, Koushik K ^a   Amenta, Peter S ^a   Yokota, Kinichi ^b   Watari, Jiro ^b   Sato, Tomonobu ^b   Kohgo, Yutaka ^b   Das, Kiron M ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Colonic phenotype; COX 2; Das 1 monoclonal antibody; Gastric cancer; Gastric intestinal metaplasia; H. pylori

Indexed keywords

CYCLOOXYGENASE 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DAS 1; UNCLASSIFIED DRUG; ANTIBODY; DAS 1 PROTEIN, HUMAN; DAS-1 PROTEIN, HUMAN;

ARTICLE; CANCER RISK; CLINICAL ARTICLE; COLON MUCOSA; DISEASE ASSOCIATION; EVALUATION; GASTRIC INTESTINAL METAPLASIA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; JAPAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RISK FACTOR; STOMACH CANCER; STOMACH CARCINOMA; STOMACH TUMOR; ADENOCARCINOMA; ENZYMOLOGY; METABOLISM; METAPLASIA; MICROBIOLOGY; PRECANCER; STAINING; STOMACH MUCOSA;

ADENOCARCINOMA; ANTIBODIES; CYCLOOXYGENASE 2; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METAPLASIA; PHENOTYPE; PRECANCEROUS CONDITIONS; STAINING AND LABELING; STOMACH NEOPLASMS;

EID: 33645813208     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000196461.15186.0d     Document Type: Article

References (46)

1. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter Pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127-1131.
2. International Agency for Research on Cancer. Schistosomes, Liver Flukes, and Helicobacter Pylori. Lyon, France: IARC, 1994:1-241.
3. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol. 1995;19(suppl 1):37-43.
4. Matsukura N, Susuki K, Kawachi T, et al. Distribution of marker enzymes and mucin in intestinal metaplasia in human stomach and relation of complete and incomplete types of intestinal metaplasia to minute gastric carcinoma. J Natl Cancer Inst. 1980;65:231-240.
5. Jass JR, Filipe MI. A variant of intestinal metaplasia associated with gastric carcinoma: a histochemical study. Histopathology. 1979;3:191-199.
6. Segura DI, Montero C. Histochemical characterization of different types of intestinal metaplasia in gastric mucosa. Cancer. 1993;52:498-503.
7. Silva S, Filipe MI. Intestinal metaplasia and its variants in the gastric mucosa of Portuguese subjects: a comparative analysis of biopsy and gastrectomy material. Hum Pathol. 1986;17:988-995.
8. Filipe MI, Munoz N, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer. 1994;57:324-329.
9. Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut. 1991;32:1110-1113.
10. Ectors N, Dixon MF. The prognostic value of sulphomucin positive intestinal metaplasia in the development of gastric cancer. Histopathology. 1996;10:1271-1277.
11. Ramesar KC, Sanders DS, Hopwood D. Limited value of type III intestinal metaplasia in predicting risk of gastric cancer. J Clin Pathol. 1987;40:1287-1290.
12. Baracchini P, Fulcheri E, Lapertosa G. Patterns of intestinal metaplasia in gastric biopsies: a comparison of different histochemical classifications. Histochem J. 1991;23:1-9.
13. Das KM, Sakamaki S, Vecchi M, et al. The production and characterization of monoclonal antibodies to human colonic antigen associated with ulcerative colitis: cellular localization of the antigen by using the monoclonal antibody. J Immunol. 1987;139:77-84.
14. Halstensen TS, Das KM, Brandtzaeg P. Epithelial deposits of immunoglobulin G1 and activated complement co-localize with the Mr 40K colonic autoantigen in ulcerative colitis. Gut. 1993;34:650-657.
15. Das KM, Prasad I, Garla S, et al. Specialized Barrett's epithelium shares a colon epithelial epitope as detected by a novel monoclonal antibody. Ann Intern Med. 1994;120:753-756.
16. Onuma EK, Amenta PS, Jukkola AF, et al. A phenotypic change of small intestinal epithelium to coloncytes in small intestinal adenomas and adenocarcinomas. Am J Gastroenterol. 2001;96:2480-2485.
17. Mirza ZK, Das KK, Slate J, et al. Gastric intestinal metaplasia as detected by monoclonal antibody is highly associated with gastric adenocarcinoma. Gut. 2003;52:807-812.
18. Kargman S, Charleson S, Cartwright M, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology. 1996;111:445-454.
19. Arias-Negrete S, Keller K, Chadee K. Proinflammatory cytokines regulate cyclooxygenase-2 mRMA expression in human macrophages. Biochem Biophys Res Commun. 1995;208:582-589.
20. DuBois RN, Tsujii M, Bishop P, et al. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am J Physiol. 1994;266:G822-G827.
21. Kargman SL, O'Neill GP, Vickers PJ, et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 1995;55:2556-2559.
22. Hilda T, Yatabe T, Achiwa H, et al. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specially in adenocarcinomas. Cancer Res. 1998;58:3761-3764.
23. Hwang D, Scollard D, Byrne J, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998;00:455-460.
24. Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinoma. Cancer Res. 1998;58:2929-2934.
25. Ebherhat CE, Coffey RJ, Radhika A, et al. Up regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183-1188.
26. Ristimäki A, Honkanen N, Jänkälä H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276-1280.
27. Uefuji K, Ichikura T, Mochizuki H, et al. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J Surg Oncol. 1998;69:168-172.
28. Sung JJY, Leung WK, Go MYY, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol. 2000;157:729-735.
29. McCarthy JC, Crofford LJ, Greenson J, et al. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol. 1999;94:1218-1223.
30. Fu S, Ramanujam KS, Wong A, et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology. 1999;116:1319-1329.
31. Plummer M, Buiatti E, Lopez G, et al. Histological diagnosis of precancerous lesions of the stomach: a reliability study. Int J Epidemiol. 1997;26:716-720.
32. Varanasi RV, Ramanujam KS, Wilson KT. A soluble factor from Helicobacter pylori induces expression and activity of cyclooxygenase-2. Gastroenterology. 1998;114:A1107.
33. Giardiello FM. Sulindac and polyp regression. Cancer Metastasis Rev. 1994;13:279-283.
34. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells over-expression prostaglandin endoperoxide synthase 2. Cell. 1995;83:493-501.
35. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res. 2000;6:135-138.
36. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993;122:518-523.
37. McLemore TL, Hubbard WC, Litterst CL, et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 1998;58:3140-3147.
38. Goodwin JS, Bankhurst AD, Messener RP. Suppression of human T-cell mitogenesis by prostaglandin; existence of prostaglandin-producing suppressor cells. J Exp Med. 1977;146:1719-1734.
39. Craanen ME, Dekker W, Blok P, et al. Intestinal metaplasia and Helicobacter pylori: an endoscopic-bioptic study of gastric antrum. Gut. 1992;33:16-20.
40. Murakami T. Pathomorphological diagnosis: definition and gross classification of early gastric cancer. In: Murakami T, ed. Early Gastric Cancer: Gann Monograph on Cancer Research 11. Tokyo, University of Tokyo Press, 1971:53-55.
41. Green PHR, O'Toole KM, Slonim D, et al. Increasing incidence and excellent survival of patients with early gastric cancer: experience in a United States medical center. Am J Med. 1988;85:658-661.
42. Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg. 1993;218:582-592.
43. Hau X, Bishop AE,Wallace M, et al. Early expression of cyclooxygenase-2 during sporadic colorectal carcinogenesis. J Path. 1999;187:295-301.
44. Jacoby RF, Marshall DJ, Newton MA, et al. Chemoprevention of spontaneous intestinal adenomas in the Apc mini-mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. 1996;56:710-714.
45. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell. 1996;87:803-809.
46. Bringaze WL, Chappuis CW, Cohn I, et al. Early gastric cancer: 21 year experience. Ann Surg. 1986;204:103-107.